Emergency reversal of anticoagulation: from theory to real use of prothrombin complex concentrates. A retrospective Italian experience. (abre uma nova janela)

Barillari G, Pasca S, Barillari A, De Angelis V.

Fonte‎: Blood Transfus 2012;10(1):87-94.

Indexado‎: PubMed 22044952

DOI‎: 10.2450/2011.0030-11

https://www.ncbi.nlm.nih.gov/pubmed/22044952 (abre uma nova janela)

Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. (abre uma nova janela)

Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, Dunn AS, Kunz R; American College of Chest Physicians.

Fonte‎: Chest 2012;141(2 Suppl):e326S-50S.

Indexado‎: PubMed 22315266

DOI‎: 10.1378/chest.11-2298

https://www.ncbi.nlm.nih.gov/pubmed/22315266 (abre uma nova janela)

Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. (abre uma nova janela)

Goldstein JN, Refaai MA, Milling TJ Jr, Lewis B, Goldberg-Alberts R, Hug BA, Sarode R.

Fonte‎: Lancet 2015;385(9982):2077-87.

Indexado‎: PubMed 25728933

DOI‎: 10.1016/S0140-6736(14)61685-8

https://www.ncbi.nlm.nih.gov/pubmed/25728933 (abre uma nova janela)

Long-term safety and efficacy of a pasteurized nanofiltrated prothrombin complex concentrate (Beriplex P/N): a pharmacovigilance study. (abre uma nova janela)

Hanke AA, Joch C, Görlinger K.

Fonte‎: Br J Anaesth 2013;110(5):764-72.

Indexado‎: PubMed 23335567

DOI‎: 10.1093/bja/aes501

https://www.ncbi.nlm.nih.gov/pubmed/23335567 (abre uma nova janela)

Emergency reversal of warfarin anticoagulation. (abre uma nova janela)

Lin Y, Callum J.

Fonte‎: CMAJ 2010;182(18):2004.

Indexado‎: PubMed 21078740

DOI‎: 10.1503/cmaj.100983

https://www.ncbi.nlm.nih.gov/pubmed/21078740 (abre uma nova janela)

Recent advances in the development of specific antidotes for target-specific oral anticoagulants. (abre uma nova janela)

Mo Y, Yam FK.

Fonte‎: Pharmacotherapy 2015;35(2):198-207.

Indexado‎: PubMed 25644580

DOI‎: 10.1002/phar.1532

https://www.ncbi.nlm.nih.gov/pubmed/25644580 (abre uma nova janela)

Idarucizumab for dabigatran reversal - full cohort analysis. (abre uma nova janela)

Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L, Weitz JI

Fonte‎: N Engl J Med 2017;377(5):431-41.

Indexado‎: PubMed 28693366

DOI‎: 10.1056/NEJMoa1707278

https://www.ncbi.nlm.nih.gov/pubmed/28693366 (abre uma nova janela)

Oral anticoagulation in surgical procedures: risks and recommendations. (abre uma nova janela)

Torn M, Rosendaal FR.

Fonte‎: Br J Haematol 2003;123(4):676-82.

Indexado‎: PubMed 14616972

https://www.ncbi.nlm.nih.gov/pubmed/14616972 (abre uma nova janela)